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It tookalmost aquarterof acenturyfrom the earliest indica- 
tion that steroid hormones play a role in transcriptional 
control, triggered by the observation by Ulrich Clever of 
ecdysoneinduced giant chromosome puffs, and from the 
earliest detection of steroid hormone receptors (SHRs) 
to the cloning of their genes (reviewed by Evans, 1988). 
Although availability of the first SHR cDNA clones 10 years 
ago triggered the isolation of the now huge superfamily 
of nuclear receptors by homology screening with the DNA- 
binding domain (DBD) (Mangelsdorf and Evans, 1995 [this 
issue of Cell]; Thummel, 1995 [this issue of CeW]), the 
vertebrate SHRs have remained a distinct class that are 
different in several respects from all other nuclear re- 
ceptors. 
Prologue: The Main Actors 
SHRs exert their influence in embryonic development and 
adult homeostasis as hormone-activated transcriptional 
regulators. Their modular structure, consisting of a DBD, 
nuclear localization signals, a ligand-binding domain 
(LBD), and several transcriptional activation functions 
(AFs) (Figure l), is conserved with other members of the 
nuclear receptor family. Unique to the SHRs is their ability 
upon activation to bind to palindromic DNA sequences, 
called hormone response elements (HREs) (Figure l), ex- 
clusively as homodimers, at least in vivo. The receptors 
for glucocorticoids, mineralocorticoids, progesterone, and 
androgens recognize the same DNA sequence (AGAACA 
as half-site) that creates a specificity problem to be dis- 
cussed later, while the estrogen receptor recognizes AGG- 
TCA, identical with the half-site used by the nonsteroid 
nuclear receptors. Mutant data, nuclear magnetic reso- 
nance studies, and X-ray analyses of DBDlHRE cocrystals 
of glucocorticoid and estrogen receptors have shown that 
half-sites are distinguished by several amino acids (origi- 
nally named the P box by Umesono and Evans, 1989) of 
a recognition helix that is coordinated by a zinc-binding 
motif and makes base-specific contacts within the major 
groove. A second zinc atom organizes both an a helix, 
which is oriented alongside the axis of the DNA, and the 
D box, responsible, at least in part, for specific homodimer- 
ization (Figure 1; reviewed by Glass, 1994). After binding 
to DNA, the receptor is thought to interact with compo- 
nents of the basal transcriptional machinery and with se- 
quence-specific transcription factors. Although a number 
of such interactions have been described, the actual 
mechanism of steroid hormone action is still far from being 
understood. We know many actors, but we do not know 
the plot. The only certainty is that there are many more 
actors than expected and that the plot they are involved 
in is neither simple nor unique. In reviewing the wealth of 
recent reports on SHRs, we will describe various levels 
of regulation, focusing on a few well-characterized exam- 
ples of hormonal induction and repression and on the in- 
sights gained by targeted disruption of the genes for SHRs. 
The Curtain Rises: The Unliganded SHR Complex 
In contrast with other nuclear receptors, all unliganded 
SHRs are associated with a large multiprotein complex of 
chaperones, including Hsp90 and the immunophilin 
Hsp56, which maintains the receptors in an inactive but 
ligand-friendly conformation (reviewed by Pratt, 1993). 
SHRs introduced into yeast can be activated upon ligand 
addition. Data obtained in mutant yeast strains suggest 
that the chaperoning proteins play an active role in keeping 
SHRs functional. In yeast strains expressing the glucocor- 
ticoid receptor, disruption of the Hsp90 homologs does 
not lead to constitutive activation of the receptor but rather 
to a significant impairment of hormone induction (Bohen 
and Yamamoto, 1993). Chaperones in addition to Hsp90 
are required for SHR function, as suggested by mutants 
of the yeast dnaJ homolog YDJl , which also associates 
with the unliganded SHR complex. In contrast with mu- 
tants found in hsp90, one ydil allele generates constitu- 
tively active estrogen and glucocorticoid receptors (Cap- 
Ian et al., 1995; Kimura et al., 1995). 
Other Members of the Cast: Basal Transcription 
Factors and Coactivators 
To regulate transcription, liganded SHRs must talk to the 
transcription initiation complex. It is currently debated 
whether transcription initiation complexes assemble at the 
TATA box in an ordered stepwise fashion (TFIID > TFIIB 
> RNA polymerase II + TFIIF > TFIIE > TFIIH) or are 
recruited as preformed complexes. Such preformed holo- 
enzyme complexes, containing RNA polymerase II and all 
relevant general transcription factors along with several 
additional polypeptides, exist in yeast (Kim et al., 1994; 
Koleske and Young, 1994) and in higher eukaryotes (Ossi- 
pow et al., 1995). 
SHRs have been shown to interact in vitro directly with 
components of the transcription initiation complex (re- 
viewed by Tsai and O’Malley, 1994), but the physiological 
significance of these interactions remains unclear. There 
have also been indications for the existence of coactiva- 
tors that would act as bridging factors between SHRs and 
the transcription initiation complex. A number of such in- 
termediary factors that interact with AF2 at the C-terminus 
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of SHR (Figure 1) in an agonist-dependent fashion have 
been identified (Halachmi et al., 1994). One of them, 
RIP140, binds only to transcriptionally active variants of 
estrogen receptor and appears to interact with estrogen 
receptor in vivo (CavaiWs et al., 1995). Another protein, 
TlFl , interacts with retinoid X receptor y (RX@) and estro- 
gen and progesterone receptors and belongs to a group 
of so-called RING proteins (Le Douarin et al., 1995). The 
RING family includes PML, the transcription factor to 
which retinoic acid receptor a (RARa) is fused in acute 
promyelocytic leukemia, which itself enhances transacti- 
vation by progesterone receptor (Guiochon-Mantel et al., 
1995), and the estrogen-responsive finger protein Efp (ln- 
oue et al., 1993). As estrogens also induce expression of 
the progesterone receptor, complex cascades of hormone 
regulation as in insects (Thummel, 1995) may also exist 
in mammals. 
Another AF2-binding protein, SUGl, interacts with sev- 
eral nuclear receptors, including SHRs, and is a compo- 
nent of the RNA polymerase II holoenzyme (see 
Mangelsdorf and Evans, 1995). Therefore, SUGl could 
be contacted by SHR for recruiting the holoenzyme. Addi- 
tional SHR-interacting proteins have been identified 
(Oiiate et al., 1995), and it is also possible that the action 
of coactivators presupposses the ligand-dependent dis- 
placement of corepressors, as described for other nuclear 
receptors (reviewed by Mangelsdorf and Evans, 1995). 
The emerging picture outlines several possible interac- 
tions of SHRs with components of the initiation complex 
but also with a number of intermediary factors. The latter 
probably form a large family with differential affinities for 
various SHRs. Sorting out the meaning of these interac- 
tions is a challenge for the near future. 
Cross-Talk: To Be or Not to Be-Active 
SHRs are not only capable of stimulating gene activity, 
but are also competent transcriptional repressors. Theo- 
retically, transcriptional repression occurs by competition 
for the DNA-binding site (see examples in Thummel, 
1995), by competition for common mediators to the tran- 
scription initiation complex, or by sequestration of the tran- 
scription factors into inactive forms. The last of these pos- 
sible mechanisms is exemplified in the transcrip0onal 
interference of nuclear receptors with two groups of tran- 
scription factorsof particular physiologic importance, AP-1 
and NF-~6. 
Inhibition of AP-l-dependent genes by nuclear recap- 
tors is transcriptional and rapid, does not require protein 
synthesis, and can be traced to an interaction of AP-1 with 
nuclear receptors (reviewed by Schijle and Evans, 1991; 
Saatcioglu et al., 1994; Herrlich and Ponta, 1994). The 
relationship is mutual in that elevated expression of AP-1 
subunits or their activation in response to growth factors 
or phorbol ester inhibits HRE promoters. As an important 
feature of this mutual inhibition, the interfering factor does 
not seem to contact DNA, and the repressed factor re- 
mains DNA bound. No major change in genomic dimethyl 
sulfate footprint has been detected at the AP-1 site of the 
glucocorticoid-repressed endogenous collagenase pro- 
moter (Kiinig et al., 1992) nor over the HRE of the glucocor- 
ticoid-induced and phorbol ester-repressed (and thus 
probably AP-1 -repressed) tyrosine aminotransferase gene 
(Reik et al., 1994). The mutual interference and the stoichi- 
ometry suggested from cotransfection experiments argue 
for direct interaction between SHR and AP-1. Direct inter- 
action occurs between in vitro translated glucocorticoid 
receptor and Jun (reviewed by Yamamoto et al., 1993; 
Saatcioglu et al., 1994; Herrlich and Ponta, 1994), but 
there is yet no convincing proof of its in vivo significance. 
The AP-1 inhibitory property of SHRs is clearly distinct 
from their transactivating function. It is ligand dependent 
but appears to occur at lower ligand concentration than 
transactivation (Jonat et al., 1990; see references in Saat- 
cioglu et al., 1994). Several antiglucocorticoids, antipro- 
gestins, and antiandrogens interfere with DNA binding 
(e.g., Becker et al., 1986; Truss et al., 1994; Heck et al., 
1994), but induce transrepression (Heck et al., 1994), sug- 
gesting that different ligands can bring about substantially 
different SHR conformations. Repressing and activating 
properties of SHRs are further discriminated by receptor 
mutations (Heck et al., 1994; Helmberg et al., 1995). In 
particular, mutants that cannot bind to DNA, mutants with 
defective AFs, and D box mutants that (in case of the 
glucocorticoid receptor, with no known other dimerization 
interphase) cannot dimerize repress AP-1 -dependent pro- 
moters perfectly well, presumably as monomers. Mutual 
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repression requires N-terminal sequences of SHRs and 
the basic-leucine zipper region of Jun (see also discussion 
in Saatcioglu et al., 1994). Many of these conclusions rely 
on cotransfection experiments and therefore need to be 
taken with caution. 
How can bona fide transcription factors be converted 
into repressors? An interesting hint has come from the 
observation that glucocorticoid receptor and Jun homodi- 
mers synergize, while glucocorticoid receptor represses 
Fos-Jun heterodimers (Yamamoto et al., 1993; Teurich 
and Angel, 1995), which suggests conformational changes 
by protein-protein interaction as basis for altered activity. 
An influence of DNA on SHR conformation has been pos- 
tulated (reviewed by Yamamoto et al., 1993; Lefstin et al., 
1994). While well known for RXR heterodimers (Mangels- 
dorf et al., 1991; Saatcioglu et al., 1994), data for glucocor- 
ticoid receptor modulation by so-called negative HREsand 
composite elements are not persuasive. Binding of gluco- 
corticoid receptor to such elements has yet only been 
shown in vitro (but not in vivo, e.g., by genomic foot- 
printing) and often requires high concentration of recombi- 
nant receptor. 
It therefore appears that, as a common principle, SHRs 
can exist in a transactivating or a repressing conformation 
in which the activation domains are disguised (Figure 2). 
Interacting proteins and ligands convert one form into the 
other. Protein-protein interaction can be mutual, and not 
only the synergy but also the inhibition occur with only 
one factor bound to DNA. It is not yet clear whether these 
rules of mutual interactions as described for SHRs and 
AP-1 can be applied to other transcription factors such as 
GATAl and Spil and to putative cell type-specific factors 
modulating SHR transcription factor cross-talk, all of which 
we have not covered here. 
The interference of SHRs with the other important factor 
of the inflammatory response, NF-KB, has only recently 
been studied. Overexpression of ~65, one of the transcrip- 
tionally active subunits of NF-KB, and of glucocorlicoid 
receptor, as well as in vitro binding between p65 and re- 
ceptors for either glucocorticoid, progesterone, or estrogen 
suggest a mutual interference mechanism as for AP-1 
(Stein et al., 1993; Ray and Prefontaine, 1994; Stein and 
Yang, 1995; Caldenhoven et al., 1995; Scheinman et al., 
1995a). In keeping with this notion, interleukin-2 expres- 
sion by a leukemic cell line selected for glucocorticoid- 
inducible apoptosis is inhibited by a transactivation- 
defective glucocorticoid receptor mutant (Helmberg et al., 
1995). The glucocorticoid receptor seems to block NF-KB 
DNA binding as measured by bandshifts in vitro. Inhibition 
by glucocorticoid of promoters containing NF-KB sites 
could, on the other hand, be explained by the recent find- 
ing of rapid induction of lKBa synthesis in response to 
hormone (Scheinman et al., 1995b; Auphan et al., 1995). 
IKB traps NF-KB in the cytoplasm, and its increased syn- 
thesis may revert NF-KB binding to promoters. These inter- 
esting findings reopen the debate on the antiinflammatory 
action and induction of apoptosis by SHRs. Is the balance 
between apoptosis and survival regulators disturbed by 
the interference with a survival pathway or by induction 





Figure 2. Synergizing and Repressing Interactionsof SHRs with Other 
Transcription Factors 
In the well-known assembly with individual DNA elements in the same 
promoter (A), transcription factors in their transactivating (circle) con- 
formation interact with coactivators and, in an unknown fashion, bun- 
dle their stimuli to the transcriptional initiation complex. Two different 
transcription factors can also act from one promoter element, envis- 
aged here as synergy (6) of, e.g., a Jun homodimer at an AP-I-binding 
site with the glucocorticoid receptor and as repression (C). The latter 
interaction needs to alter the conformation of the partners (shown 
as rectangles, concealing the activation domains). The glucocorticoid 
receptor may repress as a monomer (see text) and engage corepres- 
sion. Direct protein-protein interaction of the transcription factors, per- 
haps with participation of tissue-specific additional factors, determines 
the regulatory properties. 
al., 1995; Berko-Flint et al., 1994), the relevance of nega- 
tive regulation by SHRs in the intact organism awaits con- 
vincing demonstration, e.g., by appropriate rodent or hu- 
man mutants. 
Do the Actors Need a Revolving Stage?: 
Role for Chromatin 
The interaction between proteins and DNA and among 
SHRs, transcription factors, and the initiation complex has 
to cope with the structural organization of DNA in the nu- 
cleus. Genetic analysis has revealed a widespread 
involvement of chromatin structure in gene regulation. 
Transactivation by glucocorticoid receptor in yeast re- 
quires components of the SWllSNF complex (Yoshinaga 
et al., 1992), a set of pleiotropic transactivators that coun- 
teract repressing functions of chromatin and are therefore 
important for transcription of inducible genes (Winston and 
Carlson, 1992). In human cells lacking a homolog of SWl2, 
human Brm (hBrm), transactivation by glucocorticoid re- 
ceptor is weak and can be selectively enhanced by expres- 
sion of hBrm (Muchardt and Yaniv, 1993). Like SW12 in 
yeast, hBrm is part of a large multiprotein complex that 
mediates ATP-dependent disruption of a nucleosome and 
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enables binding of GAL-linked transactivators to GALC 
binding sites in nucleosomes (Kwon et al., 1994). Asecond 
human homolog, BRGl, is a nuclear protein that can re- 
store glucocorticoid receptor-dependent transcription in 
yeast strains lacking SW12 (Khavari et al., 1993). BRGl 
binds specifically the retinoblastoma gene product Rb, 
and Rb up-regulates glucocorticoid receptor-mediated 
transactivation only in the presence of hBrm (Singh et al., 
1995). These results document the link between SHR and 
the complex cellular machinery involved in chromatin dy- 
namics and cell cycle control. 
One of the Scenes: The Mouse Mammary Tumor 
Virus Promoter 
The mouse mammary tumor virus (MMTV) promoter is 
a well-documented example of transcriptional control by 
steroid hormones. The SHRs bind to several HREs and 
facilitate the interaction of other transcription factors, in- 
cluding nuclear factor 1 (NFl) and the octamer transcrip- 
tion factor OTFl , with the MMTV promoter (reviewed by 
Truss and Beato, 1993). Nucleosomes are nonrandomly 
distributed on the MMTV promoter (Richard-Foy and 
Hager, 1987), though a more heterogeneous distribution 
of nucleosome positions is found by formaldehyde fixation 
(Fragoso et al., 1995). One dominant nucleosome phase 
found both in mammalian cells and in yeast carrying an 
MMTV promoter permits SHR binding to HREs while pre- 
cluding binding of NFI (Truss et al., 1995; Chavez et al., 
1995). This difference probably reflects the different ways 
in which various proteins recognize their cognate DNA 
sites (Figure 3). Such data imply that DNA contains confor- 
mational or topological information that is implemented in 
chromatin and modulates the accessibility to &-acting 
elements. 
Hormone induction was believed to cause a displace- 
ment of the nucleosome over the HREs, thus allowing 
free access of NFl to its binding site and transcriptional 
activation (Richard-Foyand Hager, 1987). However, geno- 
mic footprinting of the chromosomal MMTV promoter 
shows that hormone induction does not lead to displace- 
ment, but rather to a rearrangement of the nucleosome 
that enables simultaneous binding of receptors, NFl and 
OTFl (Truss et al., 1995). Since these factors cannot bind 
simultaneously to the MMTV promoter on free DNA, the 
organization in chromatin may beaprerequisiteforoptimal 
induction of the MMTV promoter. One attractive possibility 
is that the hormone-induced nucleosomal change may be 
related to the recently observed receptor-mediated recruit- 
ment of the SWllSNF complex or of other chromatin re- 
modeling factors (Figure 4). 
Knockout of the Players Provides New Insights 
into Old Problems 
Even though a wealth of information on steroid action is 
available, the generation of mice with mutations in the 
major vertebrate SHRs by homologous recombination in 
embryonic stem cells has generated new and often unex- 
pected insights. With the exception of the androgen insen- 
sitivity syndrome (reviewed by McPhaul et al., 1993) and 
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Figure 3. Influence of Nucleosomal Phase on Protein-DNA Interac- 
tions 
(A) Proteins, such as NFI or OTFl, that interact with over half the helix 
circumference (stippled) cannot bind to their nucleosomally organized 
cognate sites, irrespective of the rotational orientation of the major 
groove. 
(8) Proteins, like SHRs, which contact only a narrow sector of the 
helix (around 100°), would bind if the major groove were exposed 
(orientation l), but not if it pointed to the histone octamer (orientation 
2) (Li and Wrange, 1995). 
the recent description of a male with a mutation in the 
estrogen receptor gene (Smith et al., 1994), no complete 
loss-of-function mutation in other human or murine SHR 
genes has been described that suggested that complete 
loss of any one of these receptors might lead to embryonic 
lethality. This suspicion has been substantiated for null 
mutations in mice of the glucocorticoid receptor, but not 
for the sex steroid receptors. 
Glucocorticoid Receptor 
Disruption of the glucocorticoid receptor gene is expected 
to interfere with many physiological processes, such as 
regulation of carbohydrate, protein and lipid metabolism, 
and modulation of immune and central nervous system 
(CNS) responses. Unexpectedly, the analysis of the gluco- 
corticoid receptor-negative mice revealed that the recep- 
tor is also required for maturation of several organ sys- 
tems, e.g., lung and adrenal gland (Cole et al., 1995), 
perhaps also explaining why so far only partial loss-of- 
function mutations have been observed in humans. Most 
of the glucocorticoid receptor-deficient mice die shortly 
after birth owing to respiratory failure caused by lack of 
inflation of the lungs, likely resulting from lowered produc- 
tion of surfactants and from deficiency of a glucocorticoid- 
inducible sodium channel. The adrenals of mutant mice 
lack adrenergic chromaffine cells from day 13 of embry- 
onic development. These cells are derived from a bipoten- 
tial neural crest cell population that, depending on environ- 





Figure 4. Model for Remodeling of Chromatin by SHR 
SHR could remodel chromatin by recruiting the SWILSNF complex or 
other factors that, e.g., catalyze the displacement of histone H2A/ 
histone H2B dimers (Cbt6 et al., 1994). 
mental cues, gives rise to chromaffine cells in the 
presence of glucocorticoid or to sympathetic neurons in 
the presence of nerve growth factor. 
Sex Steroid Receptors 
Two general conclusions can be drawn from the analyses 
of mice lacking a functional receptor for either estrogens, 
progesterone, or testosterone: lack of these receptors is 
not lethal, and the balanced sex ratio observed suggests 
that their absence does not affect the processes leading 
to sex determination. Ablation implicates the progesterone 
receptor and its ligand in many functions other than preg- 
nancy (Lydon et al., 1995). Mice without progesterone re- 
ceptor develop normally, but female homozygous mice 
are infertile owing to abnormalities in the reproduction sys- 
tem. In addition to pregnancy, ovulation, luteinization, and 
mammary gland development are impaired. 
In contrast with the plethora of spontaneous human and 
rodent androgen receptor mutations, the lack of a mutation 
of the estrogen receptor suggested its involvement in 
some vital function. Therefore, it was surprising that mice 
without estrogen receptor are viable, even though they 
are severely compromised in reproductive functions (Lu- 
bahn et al., 1993). Mice of both sexes are infertile, an 
unexpected finding for males devoid of estrogen receptor. 
The testes are smaller, and the seminiferous tubules are 
structurally altered. Apparently, the estrogen receptor has 
a direct role in the spermatogenic process. In the female, 
follicular development is impaired and hemorrhagic cystic 
ovaries develop, possibly owing to excessive gonadotro- 
pin stimulation. Since one of the well-established targets 
of estrogen action is the progesterone receptor gene, the 
relative contributions of either receptor remain to be de- 
fined. 
Abnormalities of male phenotypic development due to 
an altered androgen receptor have been frequently ob- 
served in several species, including humans, rats, and 
mice. The wide phenotypic spectrum observed in patients 
with the androgen insensitivity syndrome will be of great 
value for understanding the detailed structure/function re- 
lationship of this receptor in vivo (McPhaul et al., 1993). 
Recently, amplificatiotl of the androgen receptor locus has 
been observed in hormone-insensitive prostate cancers 
(Visakorpi et al., 1995), which is likely to be of importance 
in prostate cancer development from a hormone-sensitive 
to a hormone-refractory state. 
Perspectives: The Curtain Does Not Fall 
The availability of SHR knockouts and of SHR mutant mice 
to come will help in numerous open questions touched 
upon in this review, e.g., the role of glucocorticoid receptor 
in T cell formation and apoptosis and in the control of the 
acute phase response, the in vivo significance of activating 
and repressing SHR functions, the functional significance 
of SHR variants produced from nested primers or by alter- 
native splicing (e.g., the 0 isoform of the glucocorticoid 
receptor and the A form of progesterone receptor; see 
also similar variants of nonsteroid receptors in Thummel, 
1995), SHR function in the CNS, and the role of estrogens 
in bone formation and osteoporosis and in the develop- 
ment of steroid hormone-dependent cancers. Receptor- 
deficient mice will also be a prerequisite for a critical analy- 
sis of putative nonsteroid receptor-mediated effects of 
gluco- and mineralocorticoids as well as of estradiol (Mani 
et al., 1994; Aronica et al., 1994). 
SHRs utilize the same or highly related DNA-binding 
sites. This prompts the following question: how does an 
ubiquitous hormonal signal become interpreted in a tem- 
porally and spatially restricted manner? Recent investiga- 
tions have revealed several mechanisms through which 
selectivity might be achieved. One obvious mechanism 
to achieve steroid-specific gene activation is differential 
expression of the receptor itself. Indeed, expression of 
the progesterone receptor in hepatoma cells, where it is 
normally not expressed, has led to activation of glucocorti- 
coid-dependent genes. Selective steroid transport has 
been suggested from studies in yeast (Kralli et al., 1995). 
Selective inactivation of hormone in tissues, as seen for 
glucocorticoids in the collecting ducts of the kidneys, is 
another important mechanism to guarantee selectivity 
(Funder, 1993). 
A clinically very important open question concerns the 
mechanism of mitogenic effects of steroid hormones, in 
particular the proliferative actions of estrogens and pro- 
gesterone in uterine and mammary tissues. Ovarian hor- 
mones up-regulate the transcription of immediate-early 
genes such as c-fos, c-jun, and cyclin Dl . Targeted disrup- 
tion of the cyclin Dl gene prevents proliferation of the 
mammary gland during pregnancy (Sicinski et al., 1995) 
and yields a phenotype similar to that observed in mice 
deprived of progesterone receptor (Lydon et al., 1995). 
The pathway leading to cyclin Dl activation is under inves- 
tigation and may be a target area for cancer therapy. 
This summary of recent developments shows that con- 
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trol of gene expression by steroid hormones is far more 
complex than was apparent at the time when the genes for 
SHRs were isolated. With more and more players getting 
on stage, we realize not only this complexity but also the 
persuasive role steroid hormones play in a vast number 
of physiologic and pathologic processes. 
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